10 faktów na temat famotydyny Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 20, 2022
Słowa kluczowe:
famotydyna, H2-bloker, zastosowanie w leczeniu
##plugins.themes.bootstrap3.article.main##
Abstrakt
Famotydyna jest lekiem z grupy antagonistów receptora H2 o szerokich wskazaniach terapeutycznych w leczeniu chorób kwasozależnych górnego odcinka przewodu pokarmowego. Ma ona wiele cech stanowiących o bezpieczeństwie jej stosowania, takich jak: niskie ryzyko interakcji lekowych, szybka ulga w dolegliwościach i hamowanie nocnego wydzielania kwasu. Może być stosowana w monoterapii, ale także jako terapia dodana do inhibitorów pompy protonowej, co podnosi skuteczność leczenia i skraca jego czas.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Waśko-Czopnik , D. (2022). 10 faktów na temat famotydyny . Medycyna Faktów , 15(2(55), 137-140. https://doi.org/10.24292/01.MF.0222.3
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Echizen H, Ishizaki I. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991; 21(3): 178-94. http://doi.org/10.2165/00003088-199121030-00003.
2. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet. 1991; 20(3): 218-36. http://doi.org/10.2165/00003088-199120030-00004.
3. Gladziwa U, Klotz U, Krishna DR et al. Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol. 1988; 26(3): 315-21. http://doi.org/10.1111/j.1365-2125.1988.tb05282.x.
4. Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol Suppl. 1987; 134: 55-60. http://doi.org/10.3109/00365528709090142.
5. Gitnick G. Famotidine in the USA: a review of efficacy studies. J Int Med Res. 1989; 17(suppl 1): 17A-24A.
6. Dammann HG. Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. Hepatogastroenterology. 1990; 37(suppl 1): 2-5.
7. Haruma K, Kamada T, Manabe N et al. Are proton pump inhibitors really superior to famotidine in Japanese ulcer patients? Hepatogastroenterology. 2009; 56(93): 1059-63.
8. Mills JG, Wood JR. The pharmacology of histamine H2-receptor antagonists. Methods Find Exp Clin Pharmacol. 1989; 11(suppl 1): 87-95.
9. McCullough AJ, Graham DY, Knuff TE et al. Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing. Gastroenterology. 1989; 97(4): 860-6. http://doi.org/10.1016/0016-5085(89)91489-3.
10. Ryan JR, Vargas R, McMahon FG et al. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion. Am J Med. 1986; 81(4B): 60-4. http://doi.org/10.1016/0002-9343(86)90601-7.
11. Nema H, Kato M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J Gastroenterol. 2010; 16(42): 5342-6. http://doi.org/10.3748/wjg.v16.i42.5342.
12. Yamashita Y, Kinoshita Y, Chihara K et al. [Comparison of the effects between standard doses of H2-blocker (famotidine 20 mg b.d.) and proton pump inhibitor (omeprazole 20 mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring]. Nihon Shokakibyo Gakkai Zasshi. 1994; 91(12): 2166-73.
13. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5(2): 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.
14. Fandriks L, Lonroth H, Petterson A et al. Can famotidine and omeprazole be combined on a once-daily basis? Scand J Gastroenterol. 2007; 42(6): 689-94. http://doi.org/10.1080/00365520601026665.
2. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet. 1991; 20(3): 218-36. http://doi.org/10.2165/00003088-199120030-00004.
3. Gladziwa U, Klotz U, Krishna DR et al. Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol. 1988; 26(3): 315-21. http://doi.org/10.1111/j.1365-2125.1988.tb05282.x.
4. Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol Suppl. 1987; 134: 55-60. http://doi.org/10.3109/00365528709090142.
5. Gitnick G. Famotidine in the USA: a review of efficacy studies. J Int Med Res. 1989; 17(suppl 1): 17A-24A.
6. Dammann HG. Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. Hepatogastroenterology. 1990; 37(suppl 1): 2-5.
7. Haruma K, Kamada T, Manabe N et al. Are proton pump inhibitors really superior to famotidine in Japanese ulcer patients? Hepatogastroenterology. 2009; 56(93): 1059-63.
8. Mills JG, Wood JR. The pharmacology of histamine H2-receptor antagonists. Methods Find Exp Clin Pharmacol. 1989; 11(suppl 1): 87-95.
9. McCullough AJ, Graham DY, Knuff TE et al. Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing. Gastroenterology. 1989; 97(4): 860-6. http://doi.org/10.1016/0016-5085(89)91489-3.
10. Ryan JR, Vargas R, McMahon FG et al. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion. Am J Med. 1986; 81(4B): 60-4. http://doi.org/10.1016/0002-9343(86)90601-7.
11. Nema H, Kato M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J Gastroenterol. 2010; 16(42): 5342-6. http://doi.org/10.3748/wjg.v16.i42.5342.
12. Yamashita Y, Kinoshita Y, Chihara K et al. [Comparison of the effects between standard doses of H2-blocker (famotidine 20 mg b.d.) and proton pump inhibitor (omeprazole 20 mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring]. Nihon Shokakibyo Gakkai Zasshi. 1994; 91(12): 2166-73.
13. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5(2): 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.
14. Fandriks L, Lonroth H, Petterson A et al. Can famotidine and omeprazole be combined on a once-daily basis? Scand J Gastroenterol. 2007; 42(6): 689-94. http://doi.org/10.1080/00365520601026665.